Brief: Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA
20/03/2025 20:58
March 20 (Reuters) - Protagonist Therapeutics Inc PTGX.O: PROTAGONIST THERAPEUTICS- TAKEDA TO LEAD REGULATORY STRATEGY FOR RUSFERTIDE IN POLYCYTHEMIA VERA NDA PROTAGONIST THERAPEUTICS INC - TRANSITION TO TAKEDA OF LEADERSHIP FOR NDA PREPARATION UNDERWAY Further company coverage: PTGX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary